Some tech investors have witnessed catastrophic or even nightmarish losses as flagship companies like Meta and Roblox see their market values collapse. Read More...
Business Wire
Harrow Health Announces FDA Acceptance of New Drug Application for AMP-100
NASHVILLE, Tenn., February 22, 2022–Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic‑focused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) filing for AMP-100, the Company’s drug candidate for ocular surface anesthesia and intraoperative pain management during ocular surgery. The FDA has assigned the application standard review and a Prescription Drug User Fee Act (PDUFA) target action date of October 16, 2022.
Add Comment